PHAT Key Statistics, Chart & Performance
The current stock price of PHAT is 14.82 USD. In the past month the price increased by 7.31%. In the past year, price increased by 67.08%.
PHAT Latest News, Press Relases and Analysis
PHAT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.67 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.85 | 496.24B | ||
| MRK | MERCK & CO. INC. | 11.4 | 250.78B | ||
| PFE | PFIZER INC | 7.88 | 143.39B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.28 | 97.21B | ||
| ZTS | ZOETIS INC | 19.38 | 54.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 23.18B | ||
| VTRS | VIATRIS INC | 4.54 | 12.32B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.05 | 11.47B | ||
| CORT | CORCEPT THERAPEUTICS INC | 88.31 | 8.17B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.75B |
Related stock screener links
About PHAT
Company Profile
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 427 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Company Info
PHATHOM PHARMACEUTICALS INC
100 Campus Drive, Suite 102
Florham Park NEW JERSEY 07932 US
CEO: Terrie Curran
Employees: 427
Phone: 18777428466
PHATHOM PHARMACEUTICALS INC / PHAT FAQ
What does PHATHOM PHARMACEUTICALS INC do?
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 427 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Can you provide the latest stock price for PHATHOM PHARMACEUTICALS INC?
The current stock price of PHAT is 14.82 USD. The price decreased by -1.2% in the last trading session.
What is the dividend status of PHATHOM PHARMACEUTICALS INC?
PHAT does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHAT stock?
PHAT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does PHATHOM PHARMACEUTICALS INC belong to?
PHATHOM PHARMACEUTICALS INC (PHAT) operates in the Health Care sector and the Pharmaceuticals industry.
What is the Price/Earnings (PE) ratio of PHATHOM PHARMACEUTICALS INC (PHAT)?
PHATHOM PHARMACEUTICALS INC (PHAT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.82).
Is PHATHOM PHARMACEUTICALS INC (PHAT) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHAT.
PHAT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PHAT. When comparing the yearly performance of all stocks, PHAT is one of the better performing stocks in the market, outperforming 93.37% of all stocks.
PHAT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHAT. Both the profitability and financial health of PHAT have multiple concerns.
PHAT Financial Highlights
Over the last trailing twelve months PHAT reported a non-GAAP Earnings per Share(EPS) of -3.82. The EPS increased by 32.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.26% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PHAT Forecast & Estimates
15 analysts have analysed PHAT and the average price target is 22.95 USD. This implies a price increase of 54.86% is expected in the next year compared to the current price of 14.82.
For the next year, analysts expect an EPS growth of 38.5% and a revenue growth 241.49% for PHAT